secwatch.observer — SEC 8-K summary
======================================

Issuer:     Drugs Made In America Acquisition Corp. (DMAA)
CIK:        0002028614
Form:       8-K
Filed at:   2026-03-06T23:59:59+00:00
Accession:  0001213900-26-024392
Event type: leadership
Sentiment:  negative
Materiality: 0.70
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

CEO Lynn Stockwell resigns after affiliate fund irregularities; Roger Bendelac appointed CEO
--------------------------------------------------------------------------------

- Lynn Stockwell resigned as CEO, Executive Chair, and Board member of DMAA and affiliate, effective Feb 28, 2026.
- Resignation followed board request after Sponsor withdrew ~$1.1M from affiliate's account, including ~$566K overpayment and $200K for unrelated expenses; Sponsor cannot repay.
- Roger Bendelac appointed as new CEO; has 30+ years in investment banking/corporate advisory; compensation not yet determined.
- Board removed Ms. Stockwell from all positions on Feb 28, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2028614/000121390026024392/0001213900-26-024392-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2028614/000121390026024392/ea0280328-8k_drugs.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-024392

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer